In ACS, prasugrel reduces 30-day MACE and mortality vs. ticagrelor or clopidogrel; no differences for major bleeding.

In ACS, prasugrel reduces 30-day MACE and mortality vs. ticagrelor or clopidogrel; no differences for major bleeding. Ann Intern Med. 2020 Sep 15;173(6):JC27 Authors: Elgendy IY Abstract SOURCE CITATION: Baldetti L, Melillo F, Moroni F, et al. Meta-analysis comparing P2Y12 inhibitors in acute coronary syndrome. Am J Cardiol. 2020;125;1815-22. 32305225. PMID: 32926820 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32926820?dopt=Abstract

Source: Annals of Internal Medicine - September 14, 2020 Category: Internal Medicine Authors: Elgendy IY Tags: Ann Intern Med Source Type: research